QIAGEN Net Income 2010-2022 | QGEN

QIAGEN annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • QIAGEN net income for the quarter ending September 30, 2022 was $0.082B, a 38.11% decline year-over-year.
  • QIAGEN net income for the twelve months ending September 30, 2022 was $0.464B, a 22.24% decline year-over-year.
  • QIAGEN annual net income for 2021 was $0.513B, a 42.71% increase from 2020.
  • QIAGEN annual net income for 2020 was $0.359B, a 966.45% decline from 2019.
  • QIAGEN annual net income for 2019 was $-0.041B, a 121.77% decline from 2018.
QIAGEN Annual Net Income
(Millions of US $)
2021 $513
2020 $359
2019 $-41
2018 $190
2017 $40
2016 $80
2015 $130
2014 $116
2013 $69
2012 $130
2011 $96
2010 $144
2009 $138
QIAGEN Quarterly Net Income
(Millions of US $)
2022-09-30 $82
2022-06-30 $97
2022-03-31 $155
2021-12-31 $129
2021-09-30 $133
2021-06-30 $121
2021-03-31 $129
2020-12-31 $213
2020-09-30 $17
2020-06-30 $90
2020-03-31 $40
2019-12-31 $45
2019-09-30 $-161
2019-06-30 $45
2019-03-31 $30
2018-12-31 $61
2018-09-30 $60
2018-06-30 $37
2018-03-31 $32
2017-12-31 $-40
2017-09-30 $48
2017-06-30 $14
2017-03-31 $18
2016-12-31 $9
2016-09-30 $35
2016-06-30 $21
2016-03-31 $16
2015-12-31 $52
2015-09-30 $34
2015-06-30 $25
2015-03-31 $19
2014-12-31 $26
2014-09-30 $35
2014-06-30 $33
2014-03-31 $23
2013-12-31 $60
2013-09-30 $41
2013-06-30 $-52
2013-03-31 $20
2012-12-31 $38
2012-09-30 $29
2012-06-30 $33
2012-03-31 $29
2011-12-31 $-0
2011-09-30 $35
2011-06-30 $33
2011-03-31 $28
2010-12-31 $36
2010-09-30 $36
2010-06-30 $39
2010-03-31 $33
2009-12-31 $44
2009-09-30 $38
2009-06-30 $31
2009-03-31 $25
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.249B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00